Bristol-Myers Squibb Company

As of June 30, 2026, Bristol-Myers Squibb Company carries a market capitalization of 116.34B, placing it among publicly traded companies globally. Its enterprise value stands at 150.32B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bristol-Myers Squibb Company's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Bristol-Myers Squibb Company has 2.04B shares outstanding.

As of June 30, 2026, Bristol-Myers Squibb Company trades at a trailing price-to-earnings ratio of 12.51. The price-to-sales ratio is 2.36, and the price-to-book ratio stands at 5.21.

As of June 30, 2026, Bristol-Myers Squibb Company trades at an EV/EBITDA multiple of 10.40 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.06 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.33 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Bristol-Myers Squibb Company trades at an EV/FCF ratio of 10.64, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 150.32B versus a market cap of 116.34B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bristol-Myers Squibb Company maintains a current ratio of 1.53, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 201.86, indicating elevated leverage, while an interest coverage ratio of 8.36 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Bristol-Myers Squibb Company posted a return on equity (ROE) of 46.70, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 12.96 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.18, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 15.67, useful for judging operating efficiency across full business cycles. The company generates approximately 1.50M in revenue per employee across its workforce of 32,900.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.36 indicates how many times Bristol-Myers Squibb Company sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Bristol-Myers Squibb Company recorded 2.63B in income tax expense. That works out to an effective tax rate of 22.12, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 11.91B, leaving 9.28B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 2, 2026, Bristol-Myers Squibb Company's stock has gained approximately 42.05% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Bristol-Myers Squibb Company generated 49.19B in revenue and converted that into 9.28B in net income, yielding earnings per share of 4.54. EBITDA reached 14.46B, while operating income came in at 13.84B.

As of June 30, 2026, Bristol-Myers Squibb Company holds 11.07B in cash and equivalents against 45.05B in total debt, resulting in a net debt position of 34.40B. Total book value stands at 22.32B, with working capital of 9.92B providing operational flexibility.

Bristol-Myers Squibb Company produced 12.78B in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Bristol-Myers Squibb Company posted a gross margin of 70.16, reflecting its pricing power and cost economics. The operating margin of 28.14 and net profit margin of 18.87 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Bristol-Myers Squibb Company paid dividends of 2.50 per share. The dividend payout ratio of 54.98 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 10.98, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 10.06, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Bristol-Myers Squibb Company shareholders.

Bristol-Myers Squibb Company's most recent stock split took place on March 1, 1999 with a 1:2 split ratio.

As of June 30, 2026, Bristol-Myers Squibb Company has an Altman Z-Score of 3.87, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.